ChromaDex (CDXC) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
ChromaDex Corporation Reports First Quarter 2021 Financial Results
May 6, 2021 4:02 PM EDTTru Niagen® Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%.
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) today reported first quarter 2021 financial results.
First Quarter 2021 and Recent Highlights
Total net sales of $14.7 million, up 2% from $14.3 million in the year ago quarter. Tru Niagen® net sales of $12.4 million, a 12% increase from the year ago quarter. Gross margin of 62.9%, a 500 basis point increase from the year ago... More